论文部分内容阅读
2014年7月,FDA批准了Spectrum公司的组蛋白去乙酰化酶抑制剂(HDAC)belinostat(Beleodaq)用于治疗复发或难治性的罕见淋巴瘤——外周T细胞淋巴瘤(PTCL)。自2009年以来,本品是第3种获准用于这一罕见的侵袭性非霍奇金淋巴瘤(NHL)的治疗药物。另两种药物分别是2009年批准的普拉曲沙注射剂(Folotyn)及2011年批准的罗米地辛(Istodax)。
In July 2014, the FDA approved Spectrum's histone deacetylase inhibitor (HDAC) belinostat (Beleodaq) for the treatment of relapsed or refractory rare lymphoma-peripheral T-cell lymphoma (PTCL). This product is the third of its kind approved for use in this rare, aggressive non-Hodgkin's lymphoma (NHL) since 2009. The other two are Folotyn (approved in 2009) and Istodax (approved in 2011).